HUMA vs MDT

Medtronic plc (MDT) offers the better valuation at 21.

6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Humacyte, Inc. (HUMA) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Medtronic plc (MDT) delivered a total return of -27.

7%, compared to -89. 2% for Humacyte, Inc. (HUMA). Over 10 years, the gap is even starker: MDT returned +26. 5% versus HUMA's -88. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.

47β versus Humacyte, Inc. 's 3. 27β — meaning HUMA is approximately 602% more volatile than MDT relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Medtronic plc grew EPS 30.

8% year-over-year, compared to -17. 8% for Humacyte, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Medtronic plc (MDT) is the more profitable company, earning 13.

9% net margin versus -420. 2% for Humacyte, Inc. — meaning it keeps 13. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MDT leads at 17. 8% versus -1197. 7% for HUMA. At the gross margin level — before operating expenses — MDT leads at 65. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for HUMA: 177.

8% to $3. 00.

In this comparison, MDT (3.

6% yield) pays a dividend. HUMA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

47), 3. 6% yield). Humacyte, Inc. (HUMA) carries a higher beta of 3. 27 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +26. 5%, HUMA: -88. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: HUMA is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock. MDT pays a dividend while HUMA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.